CEACAM19 Antibody (1042108) [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: Flow
• Clone: 1042108
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 647

CEACAM19 Antibody (1042108) [Alexa Fluor® 647] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human CEACAM-19
  Met1-Gly157
  Accession # Q7Z692
• Specificity: Detects human CEACAM-19 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Reconstitution Instructions: Reconstitution default not known

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CEACAM19 Antibody (1042108) [Alexa Fluor® 647]

• carcinoembryonic antigen-related cell adhesion molecule 19
• CEACAM19
• CEACAM-19
• CEAL1

Background

Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).

1. Schorilas, A. et al. (2003) Gene 310:79.
2. Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
3. Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
4. Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
5. Obrink, B. (1997) Curr Opin Cell Biol 9:616.
6. Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
7. Michaelidou, K. et al. (2013) Int J Oncol 42:1770.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q7Z692()